The global demand for Hereditary Angioedema Therapeutics Market is presumed to reach the market size of nearly USD 8.97 BN by 2030 from USD 4.6 BN in 2022 with a CAGR of 8.7% under the study period 2023 - 2030.
Hereditary Angioedema (HAE) therapeutics refers to the medical interventions and treatments designed to manage and alleviate the symptoms of Hereditary Angioedema, a rare genetic disorder. HAE presents with repeated instances of acute and significant swelling (referred to as angioedema) occurring in multiple regions of the body, including the face, limbs, gastrointestinal tract, and the airway.
Market Dynamics
The increasing awareness and improved diagnostic capabilities have led to a rise in diagnosed cases, fueling the demand for therapeutic interventions. Advancements in treatment options, including novel drugs and prophylactic approaches, play a pivotal role in enhancing outcomes for individuals with HAE. The designation of many HAE therapeutics as orphan drugs, along with associated regulatory incentives, encourages pharmaceutical investment in research and development. Patient advocacy groups and global research collaborations contribute to a supportive ecosystem, fostering innovation and understanding of HAE. The expansion of market players and government initiatives, coupled with rising healthcare expenditure, further propel the market by accelerating the development, approval, and accessibility of HAE therapeutics. Overall, the market dynamics are characterized by a concerted effort to address the challenges of this rare genetic disorder and improve the quality of life for affected individuals.
The research report covers Porter’s Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of hereditary angioedema therapeutics. The growth and trends of hereditary angioedema therapeutics industry provide a holistic approach to this study.
Market Segmentation
This section of the hereditary angioedema therapeutics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Treatment
- C1-Esterase Inhibitor
- Bradykinin B2 Receptor Antagonist
- Kallikrein Inhibitor
- Others
By End-Use
By Route Of Administration
- Intravenous
- Subcutaneous
- Oral
Regional Analysis
This section covers the regional outlook, which accentuates current and future demand for the Hereditary Angioedema Therapeutics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
Global Hereditary Angioedema Therapeutics Market Share by Region (Representative Graph)

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Hereditary Angioedema Therapeutics market include BioCryst Pharmaceuticals Inc., Ionis Pharmaceuticals, CSL, Attune Pharmaceuticals, Adverum Biotechnologies Inc., KalVista Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Pharming. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.